Septerna (NASDAQ:SEPN) Price Target Raised to $60.00

Septerna (NASDAQ:SEPN) had its price target hoisted by HC Wainwright from $40.00 to $60.00 in a research report released on Wednesday, MarketBeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Septerna’s Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.15) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.37) EPS, Q4 2027 earnings at ($0.44) EPS and FY2027 earnings at ($1.41) EPS.

Other equities analysts have also recently issued reports about the company. Truist Financial raised their target price on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. Raymond James Financial restated a “strong-buy” rating and issued a $49.00 price target on shares of Septerna in a research report on Tuesday. Guggenheim raised their price objective on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Stifel Nicolaus set a $49.00 price objective on Septerna in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.33.

Septerna Trading Down 1.4%

Shares of SEPN stock opened at $44.50 on Wednesday. Septerna has a 12 month low of $10.74 and a 12 month high of $51.10. The stock has a market cap of $2.08 billion, a P/E ratio of -82.41 and a beta of 2.29. The company has a 50 day simple moving average of $35.83 and a two-hundred day simple moving average of $29.64.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.14. The business had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. As a group, equities analysts forecast that Septerna will post -1.32 earnings per share for the current year.

Insider Activity at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 25,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $7,665,196. This represents a 12.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.51, for a total value of $532,650.00. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,423,590.12. This represents a 13.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 72,828 shares of company stock worth $2,684,314. 5.80% of the stock is owned by corporate insiders.

Institutional Trading of Septerna

Several institutional investors have recently made changes to their positions in SEPN. Woodline Partners LP raised its stake in Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after purchasing an additional 282,585 shares during the period. Rhumbline Advisers lifted its holdings in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after purchasing an additional 3,323 shares in the last quarter. Geode Capital Management LLC boosted its stake in Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after purchasing an additional 78,316 shares during the period. JPMorgan Chase & Co. grew its holdings in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after buying an additional 1,315 shares in the last quarter. Finally, CW Advisors LLC purchased a new stake in Septerna during the 2nd quarter valued at approximately $133,000.

Key Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright significantly improved its Septerna earnings outlook, reducing its projected FY2026 loss to $1.15 per share from $2.17 and its FY2027 loss to $1.41 from $3.21. The firm retained a “Buy” rating and a $60 price target, suggesting analysts expect improved financial performance. HC Wainwright forecasts strong price appreciation for Septerna
• Positive Sentiment: HC Wainwright also raised its quarterly 2026 and 2027 EPS forecasts, with projected losses narrowing across every period. The revisions indicate better-than-expected operating trends or a more favorable development outlook for the clinical-stage biotechnology company. HC Wainwright earnings estimate revisions
• Positive Sentiment: JonesTrading raised its price target from $43 to $62 and assigned a “Buy” rating, while Wells Fargo increased its target from $48 to $50 and maintained an “Overweight” rating. These actions reinforce a favorable Wall Street view following Septerna’s recent earnings beat. JonesTrading raises Septerna price target
• Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: the company reported a $0.29-per-share loss versus the anticipated $0.43 loss, while revenue of $26.75 million topped the $19.22 million consensus estimate. Septerna shares rise on better-than-expected earnings
• Negative Sentiment: COO Elizabeth Bhatt sold 25,000 shares for approximately $1.1 million at an average price of $44, reducing her ownership by 12.55%. She still holds 174,209 shares, but the insider sale could weigh on sentiment—particularly after the stock’s strong recent advance. Septerna COO insider share sale

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.